Document is current
Any future updates will be listed below
-
Authors
Ruan, Dan-Yun
Huang, Wen-Wen
Li, Yongsheng https://orcid.org/0000-0003-2175-9449
Zhao, Yanqiu
Shi, Yehui
Jia, Yuming
Cang, Shundong
Zhang, Wei
Shi, Jianhua
Chen, Jun
Lin, Jie
Liu, Yunpeng
Xu, Jianming https://orcid.org/0000-0003-4467-6021
Ouyang, Weiwei
Fang, Jian
Zhuang, Wu
Liu, Caigang
Bu, Qing
Li, Manxiang
Meng, Xiangjiao
Sun, Meili
Yang, Nong
Dong, Xiaorong
Pan, Yueyin
Li, Xingya
Qu, Xiujuan
Zhang, Tongmei
Yuan, Xianglin
Hu, Sheng
Guo, Wei https://orcid.org/0000-0002-1923-6975
Li, Yalun
Li, Shengqing
Liu, Dongying
Song, Feixue
Tan, Liping
Yu, Yan https://orcid.org/0000-0001-5598-763X
Yu, Xinmin
Zang, Aimin
Sun, Chang
Zhang, Qian
Zou, Kai
Dan, Mo
Xu, Rui-Hua https://orcid.org/0000-0001-9771-8534
Zhao, Hongyun https://orcid.org/0000-0002-1251-3888
- License Information
-
More Information
Article History
Received: 13 September 2024
Revised: 20 December 2024
Accepted: 22 January 2025
First Online: 28 February 2025
Competing interests
: R.H.X. declares speaker fees from CPPC, MerckSerono, Bristol Myers Squibb, Roche, Henlius, Hutchison, Hengrui, Junshi, Qilu, and participates on advisory board for Astellas, AstraZeneca, BeiGene, MSD, Junshi, Hengrui, Innovent, CPPC, and Keymed. H.Y.Z. reports speaker fees from Qilu, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, and Sichuan Baili Pharmaceutical. C.S., Q.Z., K.Z., and M.D. are employees of CSPC. The remaining authors report no competing interests. Supplementary information to this manuscript can be found at link .
